Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, Double-Blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Quetiapine Fumarate and Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks and Quetiapine in Continuation (Abbreviated)

X
Trial Profile

Multicentre, Double-Blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Quetiapine Fumarate and Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks and Quetiapine in Continuation (Abbreviated)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary) ; Paroxetine
  • Indications Bipolar disorders; Bipolar I disorders; Bipolar II disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBOLDEN-II
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Feb 2010 Results were published in the Journal of Clinical Psychiatry.
    • 03 Sep 2008 Results were presented at ECNP 2008.
    • 02 Nov 2007 Status change from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top